Bpifrance
Biotech Investor · 14 portfolio companies
Portfolio Companies
| Company | Stage | Valuation | Focus |
|---|
| Carbios SAS | Commercial | $129.4M | — |
| Carmat | Market Approved (CE Mark) / Pivotal Trial (U.S.) | — | Cardiovascular |
| Inotrem | Phase 2 | — | Septic Shock, Inflammatory Diseases |
| Juvise Pharmaceuticals | Commercial | — | Multiple Sclerosis, Gastroenterology |
| May Health | Phase 3 | — | Women's Health, Reproductive Endocrinology |
| Metafora Biosystems | Commercial | — | Neurology, Rare Diseases |
| ARTHEx Biotech | Phase 1 | — | Neuromuscular Diseases, Genetic Disorders |
| Exeliom Biosciences | Phase 2 | — | Oncology, Gastroenterology |
| Tridek-One | Pre-clinical | — | Autoimmune Diseases, Inflammatory Diseases |
| UroMems | Pre-clinical | — | Urology |
| eCential Robotics | Commercial | — | Orthopedics, Neurosurgery |
| Ventuno Biotech | Pre-clinical | — | Oncology, Immunology |
| 4P-Pharma | Phase 2 | — | Osteoarthritis, Primary Sclerosing Cholangitis |
| Fabentech | Phase 2 | — | Infectious Disease, Biotoxicity |